Citigroup Inc Invitae Corp Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.42 - $0.72 $820 - $1,406	1,954 Added 5.5%	37,507 $23,000
Q3 2023 Nov 09, 2023	SELL	$0.6 - $1.53 $45,837 - $116,885	-76,396 Reduced 68.24%	35,553 $21,000
Q2 2023 Aug 10, 2023	SELL	$1.05 - $1.63 $5,560 - $8,632	-5,296 Reduced 4.52%	111,949 $126,000
Q1 2023 May 11, 2023	BUY	$1.2 - $2.73 $93,804 - $213,404	78,170 Added 200.05%	117,245 $158,000
Q4 2022 Feb 09, 2023	BUY	$1.71 - $3.61 $10,884 - $22,977	6,365 Added 19.46%	39,075 $72,000

Q3 2022 Nov 10, 2022	SELL	$1.9 - $8.63 $154,069 - $699,798	-81,089 Reduced 71.26%	32,710 $81,000
Q2 2022 Aug 10, 2022	SELL	$2.13 - $9.01 $409,302 - $1.73 Million	-192,161 Reduced 62.81%	113,799 $277,000
Q1 2022 May 12, 2022	SELL	$6.28 - $15.59 $1.54 Million - $3.83 Million	-245,350 Reduced 44.5%	305,960 $2.44 Million
Q4 2021 Feb 10, 2022	BUY	$14.7 - $28.67 $3.62 Million - $7.06 Million	246,175 Added 80.68%	551,310 $8.42 Million
Q3 2021 Nov 10, 2021	BUY	$24.31 - $33.6 $7.42 Million - $10.3 Million	305,135 New	305,135 $8.68 Million

7.66M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.